More than 25,000 people have volunteered so far to be infected with the novel coronavirus through 1DaySooner, an online recruitment organization, as an aid in testing vaccine candidates to prevent Covid-19. These volunteers know that Covid-19 can cause suffering and even death yet they are stepping forward, willing to risk their lives, because some researchers and academics contend that such experiments in humans could accelerate vaccine development.
As a physician and a scientist who has cared for patients and who has been involved in the development of vaccines, I feel the urgency to get a vaccine approved for global use. And I have deep admiration for the courageous volunteers who are willing to put themselves in danger.
In this situation, however, their sacrifice cannot be justified. Volunteers need to be protected from both known and unknown risks. The effort to develop a vaccine should not be jeopardized by this well-intentioned but unnecessary experiment.
advertisement
In the context of an ongoing pandemic, the conventional pace of vaccine development frustrates the public, the government, public health experts, vaccine creators, regulators, and others. It is understandable that many are seeking ways to accelerate the demonstration of safety and efficacy of vaccine candidates. The mumps vaccine, considered the fastest vaccine ever developed, took scientists four years to go from collecting viral samples to securing FDA approval in 1967. A decade or longer is more typical. Everyone is hoping that inventing, testing, obtaining approval and producing a Covid-19 vaccine might be on track to set a new record.
The practice of deliberately infecting people with disease, termed human challenge trials, has a long history. It is embedded in the origin of the very first vaccine in 1796, when Edward Jenner, an English physician, purposely infected his gardeners 8-year-old son with cowpox after observing that people previously infected with cowpox, a relatively mild disease, seemed protected from smallpox, one of the deadliest scourges of the time.
advertisement
Now, in the midst of the coronavirus pandemic, human challenge studies are being considered again.
In the June 1 issue of the Journal of Infectious Diseases, Nir Eyal, Marc Lipsitch, and Peter G. Smith argue that this approach could accelerate the development and approval of a Covid-19 vaccine by many months. That may sound tempting, but human challenge studies with live virus are unlikely to save time. Moreover, there are ethical and practical reasons for not undertaking human challenge studies with this virus. These authors, like 1DaySooners volunteers, are well-intentioned but wrong.
Those in favor of human challenge trials propose enrolling as subjects only healthy young adults, since the Covid-19 mortality rate in this group is low. Just 7% of all Covid-19-related deaths in the U.S. have occurred among those aged 25 to 54 years, compared to 80% in those over age 65. Yet the example of fatal infections in health care workers in the prime of life makes clear that even healthy non-elderly adults may succumb to the novel coronavirus.
Human challenge studies are generally contemplated only when rescue with a lifesaving treatment or intervention is available should a vaccine candidate not protect a volunteer from the disease. But there is no cure or treatment against the SARS-CoV-2 virus that can be deployed with confidence, making viral challenge particularly risky and ethically questionable.
Most people, likely including most of the volunteers, tend to think of vaccines as fully effective: They either work or dont. This belief generally stems from the success of vaccines for childhood diseases like measles and mumps. But some vaccines, especially those for adults, are much less effective: There are seasons when the flu vaccine is only 70% to 80% effective, or sometimes even less. Imagine, for a moment, that a vaccine candidate undergoing testing turns out to generate immunity in 80% of those who receive it. Then 20% will become infected with Covid-19.
An equally disturbing scenario is what if one of the first volunteers dies, either due to the play of chance, a problem with the vaccine, or the individuals genetic makeup? This is unlikely to happen but it can, and did, in another setting with consequences that stretched far beyond the single tragic death.
In 1999, Jesse Gelsinger volunteered for one of the first gene therapy trials. The 18-year-old had a rare metabolic genetic disorder, but his condition was managed with medication; he was basically healthy. He volunteered for a safety trial of a virus-based gene-therapy and died as a result. Missteps in the trial, and the subsequent controversy surrounding his death, set the field of gene therapy back by at least two decades. That hiatus deprived a generation of patients with genetic disorders of treatments.
With vaccines already a target of widespread misinformation campaigns, the death of a single volunteer would likely cause even greater damage. From a public health perspective, it would be especially disastrous if it both slowed the race to develop a coronavirus vaccine and fueled the anti-vaccination movement.
There are other ethical considerations. An important principle in human challenge studies is that subjects must give their informed consent in order to take part. That means they should be provided with all the relevant information about the risk they are considering. But that is impossible for such a new disease.
Covid-19 was initially thought to be mainly a respiratory ailment. We now know that it can damage the kidneys, circulatory system, and the heart. It was initially believed that children could not be sickened by SARS-CoV-2, but it now appears that dozens have developed a severe inflammatory syndrome. And we know nothing about potential long-term complications of Covid-19 because the disease has only been in humans for months. Taken together, this means that no volunteer is able to give true informed consent.
Given these risks, there might still be some justification for a human challenge trial if we knew for certain it would accelerate the development of an effective vaccine. But safer trials can get us to a vaccine in the same amount of time without taking on additional risk for volunteers, especially now that some vaccine candidates already have entered Phase 2 clinical trials and several others are close behind.
In a conventional trial, subjects are injected with either the experimental vaccine or placebo. They are then monitored to see if those who got the vaccine are less likely to contract the disease while going about their daily lives. In a human challenge study, things can theoretically happen more quickly, since volunteers are deliberately infected after getting the trial vaccine or placebo.
But human challenge trials take time, too. For Covid-19, subjects would likely have to receive two doses of vaccine (spaced by weeks), wait for potential immunity to develop, then be infected with the live virus and observed for weeks to months. Since the challenge trial would need to start small and be expanded only with great caution because of the risks involved, it would take months to deliver sufficient data. Safety data, in particular, would be lacking, even though this is one of the biggest issues confronting a new vaccine, because the size of the trial would be too small to garner robust safety data and data about adverse effects of the vaccine would be confounded by the administration of the live virus.
There is no short cut for determining safety.
A large-scale, conventional study could likely be conducted just as quickly. In addition, monitoring and interim analyses of conventional trials raise the possibility of some kind of conditional or emergency use approval while the trials continue. If that happened, a vaccine might be available for certain high-risk or vulnerable groups in record time, namely 12 to 18 months from laboratory to clinic.
A final issue is that the results of the proposed human challenge studies come exclusively from the experience of younger adults, and cannot be extrapolated to the elderly, who tend to have weaker immune responses and the highest Covid-19 mortality rate. The volunteers might end up having risked their own health without truly helping those who are in greatest need of vaccine protection.
The world is overwhelmed by the pandemic. It is imperative to expedite development and approval pathways without forgoing safety and effectiveness. Ascertaining the risks intrinsic to the disease versus those of a new vaccine in specific populations health care workers, first responders, the elderly, those with comorbidities, and the like is essential. But acceleration should not mean forsaking ethical concerns, putting well-intentioned volunteers at needless risk, or setting back global vaccine efforts.
Michael Rosenblatt, M.D., is the chief medical officer of Flagship Pioneering, a venture firm that creates life sciences companies. He is the former chief medical officer of Merck and former dean of Tufts University School of Medicine. He serves as an adviser to Moderna, which is developing a Covid-19 vaccine; he is not a Moderna employee or shareholder. The opinions expressed are his own and do not necessarily reflect those of Flagship Pioneering or Moderna.
The rest is here:
Challenge trials aren't the answer to a speedy Covid-19 vaccine - STAT
- The Ethical, Legal, and Social Issues Impacted by Modern ... - Hindawi - November 25th, 2022
- BSGM - The British Society for Genetic Medicine - November 25th, 2022
- Feasibility and ethics of using data from the Scottish newborn blood spot archive for research | Communications Medicine - Nature.com - October 7th, 2022
- Closing your health care practice: What you need to know - Medical Economics - October 7th, 2022
- Is the doctor's office heading for extinction? - Medical Economics - October 7th, 2022
- Abortion Access in the U.S.: What to Know on a State-By-State Level - Healthline - October 7th, 2022
- Students can create their own path with new ASU Online biology degree - ASU News Now - October 7th, 2022
- U.S. Releases an AI Bill Of Rights That Though Encouraging Won't Yet Move the Needle - JURIST - October 7th, 2022
- California Funds Research On Blocking Marijuana Monopolies And Protecting 'Legacy' Cannabis Strains - Marijuana Moment - October 7th, 2022
- Tips For Your Virtual Meetings With The FDA - Med Device Online - October 7th, 2022
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... - The Bakersfield Californian - October 7th, 2022
- MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress -... - October 7th, 2022
- Neighborhood deprivation and coronary heart disease in patients with bipolar disorder | Scientific Reports - Nature.com - October 7th, 2022
- Have Insurers Paid Too Much for Asbestos and Other Toxic Torts? - Claims Journal - August 19th, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo Singapore News - August 19th, 2022
- Neurologists Discuss the Impact of Roe v. Wade Reversal on... : Neurology Today - LWW Journals - August 19th, 2022
- Abortion ruling prompts variety of reactions from states - ABC News - August 19th, 2022
- Is pregnancy possible after multiple failed IVF attempts? Can your frozen eggs and sperm be as healthy later? - The Indian Express - August 19th, 2022
- Meet the Expert: Focus on orthopaedics and VTE - Hospital Healthcare Europe - August 19th, 2022
- Egg Donation Process: From Application to Recovery - Healthline - July 6th, 2021
- Patent protection of mRNA vaccines and regulatory authorization - Lexology - July 6th, 2021
- EAPM: Presidency bridging conference a great success, HTA compromise agreed and data on the agenda - EU Reporter - July 6th, 2021
- Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies - PRNewswire - April 4th, 2021
- Legally blind Great Falls filmmakers share their vision in national challenge - Yahoo News - April 4th, 2021
- Pfizer Announces Vaccine Is 100% Protective Against Coronavirus In Kids As Young As 12 - Yahoo News - April 4th, 2021
- How the law will change in 2021 - Lexology - February 11th, 2021
- Writing is the best medicine - The London Economic - February 11th, 2021
- Misleading glyphosate-cancer study Part 2: 'Symptom of a widespread problem'Concerns about ideological activism in science research and communications... - February 11th, 2021
- The Error of Fighting a Public Health War With Medical Weapons - WIRED - January 2nd, 2021
- Moderna, Pfizer vaccine trials were the highest of quality: vaccine expert - Yahoo Money - January 2nd, 2021
- Celebrate the new year with this New Year's Eve fireworks show in SF - Yahoo News - January 2nd, 2021
- The movie industry will strengthen again around April or May: Screenvision CEO - Yahoo Money - January 2nd, 2021
- Congress overrides Donald Trump's veto of a defense policy bill in the first such rebuke of his presidency - Yahoo News - January 2nd, 2021
- How the pandemic enabled a robot revolution - Politico - December 4th, 2020
- The mink link: How COVID-19 mutations in animals affect human health and vaccine effectiveness - The Conversation CA - November 24th, 2020
- How vaccines get made and approved in the US - The Albany Herald - November 24th, 2020
- Legalization votes bring worries of increased youth marijuana use, but evidence remains murky - AberdeenNews.com - November 24th, 2020
- Your daily 6: Third vaccine looks effective, no single 'word of the year' and Trump team called 'a national embarrassment' - Ravalli Republic - November 24th, 2020
- Cybersecurity depends on the user - Modern Diplomacy - November 20th, 2020
- It's Been Exactly One Year Since the First Case of COVID Was Found in China - Newsweek - November 20th, 2020
- Risks and benefits of an AI revolution in medicine - Harvard Gazette - November 12th, 2020
- HHS eased oversight of Covid-19 tests though it knew of problems - STAT - November 3rd, 2020
- Who won this years Nobel science prizes? - The Economist - October 8th, 2020
- Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question? - The Leaflet - October 8th, 2020
- FDA Oversight of Laboratory-Developed Tests Continues To Evolve - JD Supra - October 8th, 2020
- One Sperm Donor. 36 Children. A Mess of Lawsuits. - The Atlantic - September 15th, 2020
- Nebraska Medical Bill initiative blocked from entering the November ballots - Cannabis Health Insider - September 15th, 2020
- Poaching pressure mounts on jaguars, the Americas' iconic big cat - Mongabay.com - September 15th, 2020
- 'There is a sense of being robbed': Olympian Caster Semenya loses appeal on testosterone rule - The World - September 15th, 2020
- Global Microbiome Sequencing Market Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026|Clinical-Microbiomics A/S; Diversigen;... - September 5th, 2020
- Legal and Regulatory Issues in Genetic Information ... - August 31st, 2020
- The legal aspects of genetic testing - Medical Defence Union - August 31st, 2020
- Their view: Now is not the time to legalize marijuana - Wilkes Barre Times-Leader - August 31st, 2020
- Weighing up the potential benefits and harms of comprehensive full body health checks - Croakey - August 24th, 2020
- Soon, India will have its dedicated vaccine portal: ICMR - ETHealthworld.com - August 24th, 2020
- Two Families, Two Fates: When the Misdiagnosis is Child Abuse - The Marshall Project - August 22nd, 2020
- Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy - Endpoints News - August 22nd, 2020
- Contact tracing apps may be ineffective for reducing Covid-19 spread: Study - ETHealthworld.com - August 22nd, 2020
- Global Microbiome Sequencing Market Size 2020 Review, Growth Strategy, Developing Technologies And Forecast By 2026|Charles River; CoreBiome, Inc.;... - August 19th, 2020
- Bill Jones: Working to create a culture of education - Wilkes Barre Times-Leader - August 19th, 2020
- Whats next for abortion legislation in the U.S.? - PBS NewsHour - July 10th, 2020
- No ethics when it comes to US enemies, even in the middle of a deadly pandemic - IOL - July 10th, 2020
- IML conducts the 5th National Convention on Medicine and Law - ETHealthworld.com - July 10th, 2020
- Wayne Medicine and Wayne Law professors team up to explore legal and ethical issues of wastewater monitoring for COVID-19 - The South End - June 28th, 2020
- Trump Suspends H-1B and Other Visas That Allow Foreigners to Work in the U.S. - The New York Times - June 24th, 2020
- Could the Montreal Neuro herald a paradigm shift in scientific research? - University Affairs - June 24th, 2020
- Next-Generation Sequencing Market: Understanding The Key Product Segments And Their Future During 2020 -2025 - 3rd Watch News - June 24th, 2020
- Meet 'Gastruloid': The First Human Embryo-like Model From Stem Cells That Could Soon Save Many Babie - Science Times - June 12th, 2020
- Could these senolytic drugs halt the spread of COVID-19? - Health Europa - June 12th, 2020
- The coronavirus vaccine frontrunners have emerged. Here's where they stand - BioPharma Dive - June 12th, 2020
- Regulating marine genetic resources in areas beyond national jurisdiction - The Daily Star - June 12th, 2020
- Vaccines have saved millions of lives, but history shows missteps can prove deadly - The Boston Globe - June 12th, 2020
- Quitting smoking might reduce severe coronavirus infection risk: Study - ETHealthworld.com - May 23rd, 2020
- Where Taiwan Can Make the Most of AI - Taiwan - Taiwan Business TOPICS - May 23rd, 2020
- WHO and IOC team up to improve health through sport - ETHealthworld.com - May 18th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 15th, 2020
- Medical School: Who gets in and why - Stuff.co.nz - May 15th, 2020
- Wilson Ighodalo: Addressing Substance Abuse as a Public Health Problem - THISDAY Newspapers - May 15th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 14th, 2020
- Robert Youngjohns, Chairman of the Board, ABBYY - Interview Series - Unite.AI - May 14th, 2020